Anthropic acquires Coefficient Bio to expand AI in drug discovery

Anthropic has acquired biotech startup Coefficient Bio in a deal valued at around 400 million dollars, signaling a major push into healthcare and life sciences. The move brings a small, highly specialised team of computational biology experts into Anthropic’s growing AI division focused on scientific applications.

Coefficient Bio, founded less than a year ago by former Genentech researchers, operated largely in stealth while developing AI tools for drug discovery, research planning and regulatory strategy. Its technology is designed to support complex scientific workflows rather than general chatbot use, aligning with the increasing demand for domain specific AI in pharma and biotech.

The acquisition reflects a broader industry shift as AI companies move beyond general purpose models toward high value verticals such as life sciences. Anthropic has already introduced tools tailored to research and clinical documentation, and this deal strengthens its ambition to embed AI deeper into drug development processes.

By integrating Coefficient Bio’s expertise, Anthropic aims to accelerate innovation in areas including early stage discovery and clinical workflows, positioning itself as a key player at the intersection of AI and biopharma.